FDA Inspection 1175021 — Jean-Jacques Kiladjian, M.D., PhD
The FDA completed an inspection of Jean-Jacques Kiladjian, M.D., PhD on Jun 17, 2022 in Paris. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Jun 17, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Paris (France)
Additional Details
Clinical Investigator (CI)